PQE Group: 100+M€ in Revenues
PQE Group, the renowned Life Science consulting powerhouse, concludes the fiscal year 2023 with a 10% growth and an upwardly revised income exceeding 100 million euros in revenues. The Italian headquartered global firm, celebrated as a preferred advisor to pharma manufacturing and medical device corporations and SMEs globally, marks this success as a testament to its resilience, adaptability, and strategic vision amid the complex global landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240129526587/en/
Gilda D’Incerti, PQE Group CEO & Founder (Photo: Business Wire)
"At a time when many companies grapple with geopolitical challenges, crises, and inflation rates, PQE Group stands out not only for its resilience but for its ability to thrive in uncertain times, showcasing positive growth across all financial indicators," stated Gilda D'Incerti, PQE Group CEO & Founder. "This success is rooted in meticulous planning, strategic investments in cutting-edge technologies, and a corporate culture that values agility and innovation."
The recently concluded year for PQE Group is characterized by a distinctive focus on process optimization and digital investments. Having concluded 2022 with a remarkable 68% increase in revenues compared to the previous year, the company executed a robust reorganizational strategy in 2023, positioning PQE Group at its most efficient. A driving force behind the enhanced net revenue margin is the company's commitment to process efficiency, serving as a catalyst for a significant phase of innovation.
This is exemplified by the establishment of ReSQ-Up, the group's internal Contract Research Organization (CRO), dedicated to supporting companies in collaboration with hospitals, start-ups, and research institutes in their clinical trials for innovative products. ReSQ-Up introduces a new paradigm in clinical research, with a specific focus on women's health and the application of therapeutic cannabis. In parallel, PQE Group has expanded its global footprint with the inauguration of new offices in Canada, Saudi Arabia, Ireland and Singapore, bringing the total to 46 offices worldwide and 26 legal entities. This strategic expansion aims to connect PQE Group with burgeoning markets, particularly in Southeast Asia.
Stefano Carganico, PQE Group Chief Innovation Officer, emphasized the company's commitment to sustainability, stating: "We strategically invested in digital solutions and eco-friendly; this not only enhances our efficiency, but also contributes to environmental protection. After years of hyper growth and consolidation, we have set our sights on more ambitious and long-term goals, incorporating sustainability into our strategic process."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240129526587/en/
Contact information
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nexo Announces Landmark Crypto Partnership with Tennis Australia for Australian Open and Summer of Tennis17.12.2025 09:00:00 CET | Press Release
Nexo, the premier digital assets platform, has entered a landmark multi-year global partnership with Tennis Australia, becoming the Official Crypto Partner of the Australian Open and the Summer of Tennis, including the United Cup, Adelaide International, Brisbane International, and Hobart International. This agreement marks the first time a digital asset company has partnered with a Grand Slam tournament, affirming Nexo’s prestige, long-term vision, and leadership at the intersection of elite sport and digital assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216497915/en/ Antoni Trenchev, Co-founder, Nexo, noted: “The Australian Open stands at the intersection of excellence and ambition – precisely where Nexo positions itself. Our partnership reflects a shared commitment to disciplined performance and long-term thinking. We are honored to join Tennis Australia in elevating the sport while showcasing the value of int
Jerrod Chong, Yubico ’ s Chief Operating Officer, appointed as acting CEO17.12.2025 08:05:00 CET | Press Release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and the leading provider of hardware authentication security keys, today announced that Jerrod Chong, Yubico’s current Chief Operating Officer, has been appointed to serve as acting CEO. Mattias Danielsson will be stepping down from his role as CEO of Yubico. "I am very pleased that Jerrod has accepted the role of acting CEO. With his extensive experience in cybersecurity and twelve years in senior leadership at Yubico, I am confident that he will lead Yubico on a continued path of growth and he will ensure Yubico maintains and strengthens its leading position. On behalf of the board, I also want to extend our sincere thanks to Mattias Danielsson for his hard work and significant contributions to Yubico’s development as a respected leader and colleague over sixteen years. We deeply appreciate his commitment to Yubico over the years," says Patrik Tigerschiöld, Chairman of the Board. "Yubico is entering an excitin
VeritasChain Unveils VAP Architecture, New Auditability Research, and Confirms Submissions to 58 Regulators Globally17.12.2025 08:00:00 CET | Press Release
VeritasChain today unveiled its Verifiable AI Provenance Framework (VAP) architecture, published new research on verifiable audit trails, and confirmed informational submissions to 58 regulatory authorities across 43 jurisdictions. These milestones advance VeritasChain’s mission to establish a global framework for verifiable auditability in AI and algorithmic trading. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216433807/en/ Map indicates jurisdictions where regulatory outreach or informational submissions have been made as of Dec 2025. Verifiable AI Provenance Framework (VAP) VAP is a layered assurance architecture designed for independent verification of AI decision-making. It is not a single product, but a framework defining how cryptographic evidence and third-party verification interoperate across diverse systems. The architecture records decision-to-execution events as immutable audit trails, facilitating regulat
Outpost24 Secures New Investment to Scale its Exposure Management and Identity Security Solutions17.12.2025 08:00:00 CET | Press Release
Outpost24, a leader in exposure management and identity security, today announced a new investment from Vitruvian Partners to fuel its next phase of global growth. This significant new funding will accelerate innovation across the company's platform, with a focus on integrating AI capabilities to optimize how security teams identify and neutralize critical vulnerabilities. The only European vendor recognized as an overall leader in the 2025 KuppingerCole Leadership Compass Report for Attack Surface Management, Outpost24 delivers a distinct approach to cyber defence that empowers security teams to gain a complete understanding of their digital and human risk landscape. Last week, Outpost24 announced the acquisition of Infinipoint, a specialist in device identity, posture validation, and secure workforce access. The acquisition marks the company's entry into the Zero Trust Workforce Access market and lays the foundation for its identity security division, Specops, to offer a unified appr
New Published Data Confirms Nemluvio ® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis17.12.2025 07:00:00 CET | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1 The findings from post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs were published in the Journal of the European Academy of Dermatology and Venereology. Nemolizumab is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signalling of IL-31.2,5,6 IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis.3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in achieving rapid itch response. Atopic dermatitis and prurigo nodularis are debilitating skin conditions that significantly affect quality of life, with symptoms such as per
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom